112091-17-5

Basic information

• Product Name: 6-Chloro-nicotine
• Synonyms: (S)-6-Chloronicotine;2-Chloro-5-(1-Methyl-2-pyrrolidinyl)-pyridine;6-Chloro-nicotine
• CAS NO: 112091-17-5
• Molecular Formula: C₁₀H₁₃ClN₂
• Molecular Weight: 196.67662
• Product Categories: Heterocycles;Mutagenesis Research Chemicals;Nicotine Derivatives;Heterocycles, Mutagenesis Research Chemicals, Nicotine Derivatives
• Mol File: 112091-17-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 277.0±40.0 °C(Predicted)
• Appearance: /
• Density: 1.162±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DCM, Ethyl Acetate, Methanol
• PKA: 7.63±0.70(Predicted)
• CAS DataBase Reference: 6-Chloro-nicotine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-nicotine(112091-17-5)
• EPA Substance Registry System: 6-Chloro-nicotine(112091-17-5)

Safety Data

• Hazardous Substances Data: 112091-17-5(Hazardous Substances Data)

Usage

Chemical Properties

Orange to Red Oil

Uses

(S)-(-)-Nicotine (N412450) derivative.

Upstream product

• 74-89-5 methylamine 
• 421557-62-2 4-(6-chloropyridin-3-yl)-4-oxobutyraldehyde 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 499207-39-5 6'-methoxynicotine 
• 10516-09-3 (S)-6-hydroxy-D-nicotine 
• 67-72-1 hexachloroethane 
• 24721-92-4 1-Dimethylamino-ethanol 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 54-11-5 nicotin 
• 65-30-5 S-(-)-nicotine hemisulfate 
• 909193-59-5 (S)-6-chloro-5-iodonicotine 
• 909193-62-0 (S)-5-bromo-6-chloronicotine 
• 30315-34-5 5-((S)-1-methylpyrrolidin-2-yl)pyridin-2-ylamine 
• 2820-55-5 nicotine nitrogen oxide 

Downstream Products

• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 909193-59-5 (S)-6-chloro-5-iodonicotine 
• 913264-28-5 (S)-6-chloro-4-iodonicotine 
• 1146218-34-9 [5-((2S)-1-methylpyrrolidin-2-yl)-2-chloro(4-pyridyl)]bis(4-tert-butylphenyl)methan-1-ol 
• 1146218-35-0 [5-((2S)-1-methylpyrrolidin-2-yl)-2-chloro(4-pyridyl)]bis(2,3,4,5,6-pentafluorophenyl)methan-1-ol 
• 1360055-19-1 6-tert-Butyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-((S)-1-methyl-pyrrolidin-2-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridazin-3-yl}-phenyl)-2H-phthalazin-1-one 
• 1360057-50-6 C₃₆H₃₈FN₇O₄ 
• 1220183-70-9 4,4'-(phenylphosphinediyl)bis(2-chloro-5-((S)-methylpyrrolidin-2-yl)pyridine) 
• 1220183-69-6 [5-((2S)-1-methylpyrrolidin-2-yl)-2-chloro(4-pyridyl)]diphenylphosphine 
• 1211961-23-7 (S)-2-(2-chloro-5-(1-methylpyrrolidin-2-yl)pyridin-3-yl)ethyl benzoate 
• 1146218-28-1 (1R)-[5-((2S)-1-methylpyrrolidin-2-yl)-2-chloro(4-pyridyl)](2,3,4,5,6-pentaflurophenyl)methan-1-ol 
• 1146218-31-6 (1S)-[5-((2S)-1-methylpyrrolidin-2-yl)-2-chloro(4-pyridyl)](2,3,4,5,6-pentaflurophenyl)methan-1-ol 
• 1146218-32-7 [5-((2S)-1-methylpyrrolidin-2-yl)-2-chloro(4-pyridyl)]diphenylmethan-1-ol 
• 20069-02-7 (S)-brevicolline 

Relevant articles and documents

-

-

Synthesis of nornicotine, nicotine and other functionalised derivatives using solid-supported reagents and scavengers

The sequential use of solid-supported reagents and scavengers has led to an efficient synthesis of the natural products nornicotine 1, nicotine 2 and further fuctionalised derivatives. Also reported is a diastereoselective route to both enantiomers of nicotine 2.

A five-step synthesis of (S)-macrostomine from (S)-nicotine

A concise synthesis of (S)-macrostomine has been accomplished in five steps from natural nicotine in 19% overall yield via a pyridyne Diels - Alder cycloaddition reaction as the key step. A Kumada cross-coupling reaction on a 1-chloroisoquinoline intermediate provided the natural product.

CONJUGATES FOR PREVENTION OR TREATMENT OF NICOTINE ADDICTION

PROBLEM TO BE SOLVED: To provide nicotine-derived haptens, nicotine-derived hapten-carrier conjugates, and vaccine compositions containing the conjugates, which are useful for enhancing smoking quit rates or reducing smoking relapse rates in smoking cessa

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Hydroxyarylketones via Ring-Opening of lactones with aryllithium reagents: An expedient synthesis of ( )-anabasamine

The regioselective ring-opening of lactones (δ-valerolactone and γ-butyrolactone) with aryllithium reagents is reported for the construction of a series of δ-hydroxy aryl ketones and γ-hydroxy aryl ketones. Application of this method for the expeditious syntheses of ( )-anabasamine and its nicotine-related analogue are also described.